Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

PR Newswire 8 days ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

PR Newswire 12 days ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

PR Newswire November 12, 2024

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire November 11, 2024

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

PR Newswire November 5, 2024

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

PR Newswire November 4, 2024

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

PR Newswire October 17, 2024

Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024

PR Newswire October 7, 2024

Moleculin to Present at Two Upcoming Investor Conferences

PR Newswire October 4, 2024

Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma

PR Newswire September 23, 2024

Moleculin Participates in Virtual Investor "What this Means" Segment

PR Newswire September 16, 2024

Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

PR Newswire September 9, 2024

Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PR Newswire September 3, 2024

Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

PR Newswire August 26, 2024

Moleculin Announces Closing of up to $16.5 Million Public Offering

PR Newswire August 19, 2024

Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 14, 2024

Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET

PR Newswire August 5, 2024

Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial

PR Newswire August 1, 2024

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

PR Newswire July 10, 2024

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

PR Newswire June 14, 2024